How Are Analysts Approaching Shares of Fate Therapeutics, Inc. (NASDAQ:FATE)?

Fate Therapeutics, Inc. (NASDAQ:FATE) currently has an Average Broker Rating of 1.18. The ABR rank within the industry stands at 11. This number is based on the 11 sell-side firms polled by Zacks.  

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Each brokerage research report carries with it some form of recommendation. The brokerage firms may use different lingo for their rating systems (like saying Outperform instead of Buy), but they can all be properly sorted into our 5 level classification system that is now the industry standard. Each of the 5 classifications has a value associated with it to help compute the ABR. 

As the name implies the ABR will show you the Average of Brokerage Recommendations on a given stock. The benefit is that you quickly get a snapshot of where Wall Street stands on a stock without having to read a mountain of research reports.

Broker recommendations are made by brokerage firms (for example, JP Morgan) and are not an outright recommendation to buy or sell a share, but instead give an indication of how the broker thinks the company will perform relative to its sector. Their recommendations are issued over a particular period of time. The recommendations provided in the Research Centre are shown on a 75 day rolling basis. Each brokerage firm has its own way of rating that may make it difficult to compare broker recommendations between the brokerage houses.

For example, at one brokerage “buy” may be the strongest recommendation, while at another “buy” could be second to a “strong buy” rating. The second-highest ratings also have a number of different other names: “accumulate”, “outperform”, “moderate buy” or “overweight”.

Analysts on a consensus basis are expecting that the stock will reach $25.55 within the year.

Dedicated investors tend to spend a lot of time trying to decipher the correct procedure for beating the stock market. This may involve figuring out a proper strategy, and deciding which stocks to start with when constructing a portfolio. Building a portfolio does not have to be a frantic race. In fact, not rushing into things may end up putting the investor in a good position to succeed. There are times when tough decisions need to be made when dealing with the equity market. Spending enough time to assess all the possibilities before making an investing decision may pay off down the road. As most investors know, there is no magic formula for coming out a winner in the stock market. Acquiring the most possible knowledge about the markets and individual stocks can play a vital role in the long-term success of the individual investor. 

Research analysts are predicting that Fate Therapeutics, Inc. (NASDAQ:FATE) will report earnings of $-0.38 per share when the firm issues their next quarterly report. This is the consensus earnings per share number according to data from Zack’s Research.

Fate Therapeutics, Inc. (NASDAQ:FATE) closed the last session at $15.34 and sees an average of 600976.63 shares trade hands in each session. The 52-week low of the stock stands at $11.5 while the current level stands at 31.36% of the 52-week High-Low range. Looking further out we can see that the stock has moved -22.34% over the past 12 weeks and 16.52% year to date.

Most recently Fate Therapeutics, Inc. (NASDAQ:FATE) posted quarterly earnings of $-0.36 which compared to the sell-side estimates of -0.38. The stock’s 12-month trailing earnings per share stands at $-1.22. Shares have moved $-0.5 over the past month and more recently, $3.53 over the past week heading into the earnings announcement. There are 7 analyst projections that were taken into consideration from respected brokerage firms.

Investors studying the fundamentals might be conducting in-depth company research before deciding when to purchase a particular stock. The investor checklist may include studying the scope of a company’s competitive industry advantage, examining company management, and trying to get a general feel if the stock is valued properly. Once the decision is made that the company is a good fit for the portfolio, it may be wise to assess whether or not current conditions and price levels indicate proper levels for share purchase. The timing of purchasing a researched stock obviously comes with some level of trepidation. Investors will only know in the future whether they got in at the right price. A stock that looks very attractive today may not be as attractive in the future. Sometimes the investor will just have to trust their research and instinct when purchasing shares. 

10 analysts rate Fate Therapeutics, Inc. a Buy or Strong Buy, which is 90.91% of all the analyst ratings.

Leave a Reply

Your email address will not be published. Required fields are marked *

*